logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
7/6/2020 8:37:24 AM Aimmune Appoints Narinder Singh As EVP Of Technical Operations
6/8/2020 8:10:29 AM Aimmune Therapeutics Announces Two-year Data That Suggest Long-term Efficacy Of Daily Treatment With PALFORZIA
6/1/2020 8:14:11 AM Aimmune To Present Important Long-term Safety, Efficacy And Immunological Data From ARC004
2/5/2020 8:44:41 AM Aimmune Therapeutics Reports Addl $200 Mln Equity Investment By Nestl Health Science
2/5/2020 8:10:01 AM Aimmune Therapeutics Says Obtains Exclusive Worldwide Rights To Xencor's XmAb(r)7195 For NexGen Food Allergy Treatments
2/5/2020 8:08:05 AM Aimmune Licenses Exclusive Worldwide Rights To Xencor's XmAb 7195
7/2/2019 8:43:02 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
6/28/2019 7:11:32 AM Aimmune Therapeutics Submits MAA To EMA For AR101
6/11/2019 12:59:04 PM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
6/6/2019 8:41:41 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
6/4/2019 7:04:38 AM Aimmune Therapeutics Announces New Data From Phase 3 PALISADE Follow-on Study Of AR101 For Peanut Allergy